Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study

BACKGROUND: Some patients with advanced or recurrent, epidermal growth factor receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression. METHODS: We analysed a cohort of 577 patients with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ESMO Open
Главные авторы: Goto, Yasushi, Tanai, Chiharu, Yoh, Kiyotaka, Hosomi, Yukio, Sakai, Hiroshi, Kato, Terufumi, Kaburagi, Takayuki, Nishio, Makoto, Kim, Young Hak, Inoue, Akira, Hasegawa, Yoshinori, Isobe, Hiroshi, Tomizawa, Yoshio, Mori, Yoshiaki, Minato, Koichi, Yamada, Kazuhiko, Ohashi, Yasuo, Kunitoh, Hideo
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2017
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604715/
https://ncbi.nlm.nih.gov/pubmed/29018574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000214
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы